

Form PTO-1595 (Rev. 03-09)
OMB No. 0651-0027 (exp. 03/31/2009)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies) Valentis, Inc. Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies) Name: <u>Urigen Pharmaceuticals, Inc.</u> Internal Address: <u>Suite 330</u> Street Address: <u>1700 North Broadway</u> City: <u>Walnut Creek</u> State: <u>California</u> Country: <u>USA</u> Zip: <u>94596</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance/Execution Date(s): Execution Date(s) <u>July 19, 2007</u> <input type="checkbox"/> Assignment <input checked="" type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other _____	4. Application or patent number(s): <input type="checkbox"/> This document is being filed together with a new application. A. Patent Application No.(s) (See Attachment A) B. Patent No.(s) (See Attachment A) Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
5. Name and address to whom correspondence concerning document should be mailed: Name: <u>D. Benjamin Borson, Ph.D.</u> Internal Address: <u>Suite 200</u> Street Address: <u>1078 Carol Lane</u> City: <u>Lafayette</u> State: <u>CA</u> Zip: <u>94549</u> Phone Number: <u>(925) 310-2060</u> Fax Number: <u>(925) 310-2061</u> Email Address: <u>bborson@borsonlaw.com</u>	6. Total number of applications and patents involved: <u>eight</u> 7. Total fee (37 CFR 1.21(h) & 3.41) \$ <u>320.00</u> <input checked="" type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title) 8. Payment Information Deposit Account Number <u>504089</u> Authorized User Name <u>D. Benjamin Borson, Ph.D.</u>
9. Signature: <u>D. Benjamin Borson</u> October 6, 2010 <div style="display: flex; justify-content: space-between;"> Signature Date </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> D. Benjamin Borson, Ph.D. Name of Person Signing <div style="border: 1px solid black; padding: 2px; text-align: center;"> Total number of pages including cover sheet, attachments, and documents: 5 </div> </div>	

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

CH \$320.00 504089 11327987

Attachment A to Recordation Form Cover Sheet dated October 6, 2010
Borson Law Group, PC

Applications:

11/327,987
11/965,607
12/850,969
12/796,961

Patents:

7,026,468
6,011,148
7,807,822
7,314,746

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"URIGEN PHARMACEUTICALS, INC.", A DELAWARE CORPORATION,
WITH AND INTO "VALENTIS, INC." UNDER THE NAME OF "URIGEN PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE NINETEENTH DAY OF JULY, A.D. 2007, AT 12:29 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

2784403 8100M

070830700

*Harriet Smith Windsor*

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 5856229

DATE: 07-19-07

PATENT
REEL: 025095 FRAME: 0276

State of Delaware
Secretary of State
Division of Corporations
Delivered 12:46 PM 07/19/2007
FILED 12:29 PM 07/19/2007
SRV 070830700 - 2784403 FILE

CERTIFICATE OF MERGER

OF

VALENTIS, INC.
(a Delaware corporation)

AND

URIGEN PHARMACEUTICALS, INC.
(a Delaware corporation)

UNDER SECTION 253 OF THE GENERAL CORPORATION LAW
OF THE STATE OF DELAWARE

The undersigned corporations organized and existing under and by virtue of the General
Corporation Law of the State of Delaware,

DO HEREBY CERTIFY:

FIRST: That the name and state of incorporation of each of the constituent corporations of the
merger are as follows:

<u>NAME</u>	<u>STATE OF INCORPORATION</u>
Valentis, Inc.	Delaware
Urigen Pharmaceuticals, Inc.	Delaware

SECOND: That 100% of the outstanding stock of Urigen Pharmaceuticals, Inc. is owned by
Valentis, Inc. Inc.

THIRD: That the name of the surviving corporation of the merger is Valentis, Inc. Inc.,
which will continue its existence as said surviving corporation under the name Urigen Pharmaceuticals, Inc.

FOURTH: That the Certificate of Incorporation of Valentis, Inc. Inc., a Delaware
corporation, the surviving corporation, shall be the Certificate of Incorporation of the surviving
corporation, except that article FIRST relating to the name shall be struck and shall be substituted in lieu
therefor the following article:

"FIRST: The name of the corporation is Urigen Pharmaceuticals, Inc."

FOURTH: That the members of the Board of Directors of Valentis, Inc. unanimously adopted the following resolution by written consent on the 16th day of July, 2007:

RESOLVED, that the Company's wholly-owned subsidiary, Urigen Pharmaceuticals, Inc., be merged with and into the Company, and that upon the filing of the appropriate certificate of Merger with the Secretary of State of the State of Delaware, the Company's name shall be changed to Urigen Pharmaceuticals, Inc.

FIFTH: This merger shall be effective on July 19, 2007.

IN WITNESS WHEREOF, the undersigned have executed this Certificate this 19th day of July, 2007.

VALENTIS, INC.

By: /s/William Garner
Name: William J. Garner
Title: Chief Executive Officer

URIGEN PHARMACEUTICALS, INC.

By: /s/William Garner
Name: William J. Garner
Title: Chief Executive Officer